Tyra reports 79% response in bladder cancer trial
Tyra Biosciences (NASDAQ:TYRA) reported initial Phase 2 SURF302 results showing oral dabogratinib achieved a 79% overall response rate at the 60 mg once-daily dose in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer.










